{"disease":{"id":"solid-tumor","name":"solid tumor"},"drugs":{"marketed":[{"drug_id":"repotrectinib","indication_name":"NTRK gene fusion-positive solid tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Augtyro","generic_name":"REPOTRECTINIB","company_name":"Bristol","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":"200","mechanism":"Augtyro blocks the activity of ROS1 and NTRK kinases, which are abnormal proteins that help cancer cells grow and spread."},{"drug_id":"neo-bladder-construct","indication_name":"BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"\"Neo-Bladder\" Construct","company_name":"Wake Forest University Health Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":29,"revenue":null,"mechanism":null},{"drug_id":"zoledronic-acid","indication_name":"Bone Metastases from Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zometa","generic_name":"ZOLEDRONIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"zoledronic acid","quality_score":80,"revenue":null,"mechanism":"Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity."},{"drug_id":"chembl-chembl1983268","indication_name":"NTRK Gene Fusion-Positive Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENTRECTINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"larotrectinib","indication_name":"NTRK fusion gene-positive advanced or recurrent solid tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitrakvi","generic_name":"LAROTRECTINIB","company_name":"Bayer","drug_phase":"marketed","molecular_target":"High affinity nerve growth factor receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Vitrakvi works by blocking the activity of a specific protein called the nerve growth factor receptor."},{"drug_id":"sitravatinib","indication_name":"Solid tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sitravatinib","generic_name":"sitravatinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine kinases","drug_class":"Tyrosine kinase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"trametinib","indication_name":"Unresectable or metastatic solid tumors with BRAF V600E mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mekinist","generic_name":"trametinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 2","drug_class":"Kinase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells."},{"drug_id":"zoledronic-acid","indication_name":"Bone Metastases of Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zometa","generic_name":"ZOLEDRONIC ACID","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Farnesyl pyrophosphate synthase","drug_class":"zoledronic acid","quality_score":80,"revenue":null,"mechanism":"Zometa works by inhibiting the enzyme farnesyl pyrophosphate synthase, which is involved in the mevalonate pathway and ultimately leads to the inhibition of osteoclast activity."},{"drug_id":"zometa","indication_name":"Bone Metastases of Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zometa","company_name":"University of Arkansas","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zoledronate","indication_name":"Bone Metastases of Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zoledronate","company_name":"Children's Hospital Medical Center, Cincinnati","drug_phase":"marketed","molecular_target":"Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl2103875","indication_name":"BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (Combination with Dabrafenib)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TRAMETINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":5,"revenue":null,"mechanism":null},{"drug_id":"dostarlimab-gxly","indication_name":"Mismatch Repair Deficient Recurrent or Advanced Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"JEMPERLI","generic_name":"DOSTARLIMAB-GXLY","company_name":"GLAXOSMITHKLINE","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response."}],"pipeline":[{"drug_id":"pf-07265028","indication_name":"Advanced Solid Tumors","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07265028","generic_name":"pf-07265028","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"PF-07265028 will be administered orally","quality_score":null,"revenue":null,"mechanism":"PF-07265028 will be administered orally"},{"drug_id":"encorafenib-binimetinib-treatment","indication_name":"Solid Tumors","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Encorafenib & Binimetinib Treatment","generic_name":"encorafenib-binimetinib-treatment","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 4","quality_score":0,"revenue":null,"mechanism":"Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 4"},{"drug_id":"binimetinib-only-treatment","indication_name":"Solid Tumors","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Binimetinib only treatment","generic_name":"binimetinib-only-treatment","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Binimetinib will be administered at the same dose level (15 mg to 45 mg) as that received in the Par","quality_score":0,"revenue":null,"mechanism":"Binimetinib will be administered at the same dose level (15 mg to 45 mg) as that received in the Par"},{"drug_id":"olaparib-oral-product","indication_name":"BRCA1/2-mutated and HRD-positive advanced solid tumors","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib Oral Product","company_name":"Duke University","drug_phase":"discontinued","molecular_target":"PARP-1 and PARP-2 (poly-ADP-ribose polymerase enzymes)","drug_class":"PARP inhibitor (DNA repair inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits poly-ADP-ribose polymerase (PARP) enzymes to impair DNA repair in cancer cells with BRCA mutations or homologous recombination deficiency."},{"drug_id":"obi-999","indication_name":"Advanced solid tumors","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OBI-999","company_name":"OBI Pharma, Inc","drug_phase":"discontinued","molecular_target":"Globo H (globoside carbohydrate antigen)","drug_class":"Antibody-drug conjugate (ADC)","quality_score":null,"revenue":null,"mechanism":"OBI-999 is an antibody-drug conjugate targeting Globo H carbohydrate antigen on cancer cells to deliver cytotoxic payload."},{"drug_id":"treatment-of-encorafenib-binimetinib-cetuximab","indication_name":"Solid Tumors","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treatment of Encorafenib & Binimetinib & Cetuximab","generic_name":"treatment-of-encorafenib-binimetinib-cetuximab","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 4","quality_score":0,"revenue":null,"mechanism":"Encorafenib will be administered on a 300 mg QD schedule and binimetinib will be administered on a 4"},{"drug_id":"pf-07260437","indication_name":"Advanced or metastatic solid tumors (including ovarian, endometrial, and breast neoplasms)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07260437","generic_name":"pf-07260437","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Unknown","drug_class":"Unknown oncology compound","quality_score":null,"revenue":null,"mechanism":"Mechanism of action unknown; experimental oncology compound discontinued during Phase 1 development."},{"drug_id":"pf-07329640","indication_name":"Advanced or Metastatic Solid Tumors","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07329640","generic_name":"pf-07329640","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Data not available","drug_class":"Data not available","quality_score":null,"revenue":null,"mechanism":"Mechanism of action not disclosed in available data."},{"drug_id":"olaparib-200-300-mg-bid-daily","indication_name":"Advanced solid tumors (RP-3467 + olaparib combination)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib 200-300 mg BID, daily","company_name":"Repare Therapeutics","drug_phase":"discontinued","molecular_target":"PARP1 and PARP2 (poly(ADP-ribose) polymerase enzymes)","drug_class":"PARP inhibitor (DNA damage response inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits PARP enzymes to block DNA single-strand break repair, inducing synthetic lethality in BRCA-mutant and HR-deficient cancers."},{"drug_id":"encorafenib-only-treatment","indication_name":"Solid Tumors","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Encorafenib only Treatment","generic_name":"encorafenib-only-treatment","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Encorafenib will be self-administered at the same dose level as that received in the C4221010 Parent","quality_score":null,"revenue":null,"mechanism":"Encorafenib will be self-administered at the same dose level as that received in the C4221010 Parent"},{"drug_id":"treatment-of-encorafenib-binimetinib-ribociclib","indication_name":"Solid Tumors","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treatment of Encorafenib & Binimetinib & Ribociclib","generic_name":"treatment-of-encorafenib-binimetinib-ribociclib","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binime","quality_score":0,"revenue":null,"mechanism":"Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binime"},{"drug_id":"pf-07820435","indication_name":"Advanced solid tumors (non-small-cell lung cancer, melanoma)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07820435","generic_name":"pf-07820435","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"SARS-CoV-2 3CL protease (main protease) and/or cellular proteases in oncology indications","drug_class":"Protease inhibitor","quality_score":null,"revenue":null,"mechanism":"PF-07820435 inhibits viral or cellular proteases to disrupt essential enzymatic processes required for viral replication or tumor cell survival."}],"offLabel":[],"totalMarketed":12,"totalPipeline":12},"trials":{"data":[{"nct_id":"NCT06895681","title":"UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50000,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT05793281","title":"An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":46621,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04932525","title":"Gustave Roussy Cancer Profiling","phase":"NA","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT02457962","title":"Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03324841","title":"POA Prospective Repository","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Caris Science, Inc.","has_results":false},{"nct_id":"NCT03326479","title":"POA Retrospective Repository","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Caris Science, Inc.","has_results":false},{"nct_id":"NCT03739827","title":"Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04496375","title":"An Evaluation of Patients Access to Their Electronic Medical Records Via the IPC Connect Application","phase":"","overall_status":"UNKNOWN","enrollment_count":8000,"lead_sponsor_name":"Institut Paoli-Calmettes","has_results":false},{"nct_id":"NCT01855477","title":"CPCT-02 Biopsy Protocol","phase":"NA","overall_status":"COMPLETED","enrollment_count":6927,"lead_sponsor_name":"Foundation CPCT","has_results":false},{"nct_id":"NCT00736749","title":"Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02693535","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":4200,"lead_sponsor_name":"American Society of Clinical Oncology","has_results":false},{"nct_id":"NCT05594147","title":"An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib","phase":"","overall_status":"COMPLETED","enrollment_count":4103,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07489378","title":"NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04010240","title":"A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study","phase":"","overall_status":"COMPLETED","enrollment_count":3820,"lead_sponsor_name":"Institut Bergonié","has_results":true},{"nct_id":"NCT03486873","title":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06824792","title":"Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent System","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"NING LI","has_results":false},{"nct_id":"NCT05695638","title":"Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Morten Ladekarl","has_results":false},{"nct_id":"NCT05534178","title":"Machine Learning Model to Predict HOLS and Mortality After Discharge in Hospitalized Oncologic Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"Vall d'Hebron Institute of Oncology","has_results":false},{"nct_id":"NCT03347318","title":"Target Therapies Resistance Molecular Profiling in Patients With Neoplastic Disease","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Fondazione del Piemonte per l'Oncologia","has_results":false},{"nct_id":"NCT02530658","title":"Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT05691608","title":"MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2","phase":"NA","overall_status":"RECRUITING","enrollment_count":1800,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT01772004","title":"Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":1756,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT06466070","title":"Robotic Surgery in Pulmonary Metastasectomy","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1650,"lead_sponsor_name":"Scientific Institute San Raffaele","has_results":false},{"nct_id":"NCT07035470","title":"Biological Age Predicts 90-Day Mortality in Advanced Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1615,"lead_sponsor_name":"Ankara Etlik City Hospital","has_results":false},{"nct_id":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1609,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07426094","title":"PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Affidea Nu-med Center of Oncological DIagnostics and Therapy","has_results":false},{"nct_id":"NCT04397575","title":"The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1523,"lead_sponsor_name":"Federation Francophone de Cancerologie Digestive","has_results":false},{"nct_id":"NCT06702566","title":"The Effect of Serum Ferritin in irAE","phase":"NA","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT05166694","title":"Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions","phase":"NA","overall_status":"RECRUITING","enrollment_count":1300,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT01295827","title":"Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":1260,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT07167095","title":"90-Day Mortality After Emergency Department Discharge in Advanced Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1250,"lead_sponsor_name":"Ankara Etlik City Hospital","has_results":false},{"nct_id":"NCT03453528","title":"Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":1225,"lead_sponsor_name":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","has_results":false},{"nct_id":"NCT04762862","title":"QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1200,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT06665776","title":"HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"PharmaEssentia","has_results":false},{"nct_id":"NCT05600933","title":"Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1200,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01928394","title":"A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":1163,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT05438329","title":"First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":1123,"lead_sponsor_name":"DualityBio Inc.","has_results":false},{"nct_id":"NCT00477958","title":"Assessment Tool for Older Patients With Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1062,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05190263","title":"Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma","phase":"","overall_status":"COMPLETED","enrollment_count":1053,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT06927570","title":"A Study of HS-20122 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1050,"lead_sponsor_name":"Hansoh BioMedical R&D Company","has_results":false},{"nct_id":"NCT06336707","title":"HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1048,"lead_sponsor_name":"Hansoh BioMedical R&D Company","has_results":false},{"nct_id":"NCT01693562","title":"A Phase 1/2 Study to Evaluate MEDI4736","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":1022,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT06536257","title":"Personalised Immunotherapy Platform","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Melanoma Institute Australia","has_results":false},{"nct_id":"NCT06298773","title":"Spatial Profile of Tumors","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05416710","title":"Universal Germline Testing in the Community","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Invitae Corporation","has_results":false},{"nct_id":"NCT05785741","title":"A Study of DB-1310 in Advanced/Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"DualityBio Inc.","has_results":false},{"nct_id":"NCT06432283","title":"A Machine Learning-based Estimated Survival Model","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Zhao Siyao","has_results":false},{"nct_id":"NCT01050296","title":"Molecular Analysis Of Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}